731 related articles for article (PubMed ID: 23827675)
1. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.
Chaffer CL; Marjanovic ND; Lee T; Bell G; Kleer CG; Reinhardt F; D'Alessio AC; Young RA; Weinberg RA
Cell; 2013 Jul; 154(1):61-74. PubMed ID: 23827675
[TBL] [Abstract][Full Text] [Related]
2. Poised with purpose: cell plasticity enhances tumorigenicity.
Marjanovic ND; Weinberg RA; Chaffer CL
Cell Cycle; 2013 Sep; 12(17):2713-4. PubMed ID: 23966153
[No Abstract] [Full Text] [Related]
3. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
4. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.
Larsen JE; Nathan V; Osborne JK; Farrow RK; Deb D; Sullivan JP; Dospoy PD; Augustyn A; Hight SK; Sato M; Girard L; Behrens C; Wistuba II; Gazdar AF; Hayward NK; Minna JD
J Clin Invest; 2016 Sep; 126(9):3219-35. PubMed ID: 27500490
[TBL] [Abstract][Full Text] [Related]
7. β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness.
Sánchez-Tilló E; de Barrios O; Siles L; Cuatrecasas M; Castells A; Postigo A
Proc Natl Acad Sci U S A; 2011 Nov; 108(48):19204-9. PubMed ID: 22080605
[TBL] [Abstract][Full Text] [Related]
8. IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation.
Li Y; Wang L; Pappan L; Galliher-Beckley A; Shi J
Mol Cancer; 2012 Nov; 11():87. PubMed ID: 23174018
[TBL] [Abstract][Full Text] [Related]
9. Decrease of ZEB1 expression inhibits the B16F10 cancer stem-like properties.
Zhao F; He X; Wang Y; Shi F; Wu D; Pan M; Li M; Wu S; Wang X; Dou J
Biosci Trends; 2015 Oct; 9(5):325-34. PubMed ID: 26559025
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells.
Graham TR; Yacoub R; Taliaferro-Smith L; Osunkoya AO; Odero-Marah VA; Liu T; Kimbro KS; Sharma D; O'Regan RM
Breast Cancer Res Treat; 2010 Aug; 123(1):139-47. PubMed ID: 19921427
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
12. An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.
Qin Y; Tang B; Hu CJ; Xiao YF; Xie R; Yong X; Wu YY; Dong H; Yang SM
Oncotarget; 2016 Jan; 7(1):351-61. PubMed ID: 26540342
[TBL] [Abstract][Full Text] [Related]
13. Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Lobert S; Graichen ME; Morris K
Biochemistry; 2013 Aug; 52(32):5482-90. PubMed ID: 23869586
[TBL] [Abstract][Full Text] [Related]
14. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
Rajabi H; Alam M; Takahashi H; Kharbanda A; Guha M; Ahmad R; Kufe D
Oncogene; 2014 Mar; 33(13):1680-9. PubMed ID: 23584475
[TBL] [Abstract][Full Text] [Related]
15. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Li X; Roslan S; Johnstone CN; Wright JA; Bracken CP; Anderson M; Bert AG; Selth LA; Anderson RL; Goodall GJ; Gregory PA; Khew-Goodall Y
Oncogene; 2014 Jul; 33(31):4077-88. PubMed ID: 24037528
[TBL] [Abstract][Full Text] [Related]
16. Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs.
Dou J; He X; Liu Y; Wang Y; Zhao F; Wang X; Chen D; Shi F; Wang J
Cell Biol Int; 2014 Apr; 38(4):452-61. PubMed ID: 24339410
[TBL] [Abstract][Full Text] [Related]
17. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Wellner U; Schubert J; Burk UC; Schmalhofer O; Zhu F; Sonntag A; Waldvogel B; Vannier C; Darling D; zur Hausen A; Brunton VG; Morton J; Sansom O; Schüler J; Stemmler MP; Herzberger C; Hopt U; Keck T; Brabletz S; Brabletz T
Nat Cell Biol; 2009 Dec; 11(12):1487-95. PubMed ID: 19935649
[TBL] [Abstract][Full Text] [Related]
18. The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism.
Chu K; Boley KM; Moraes R; Barsky SH; Robertson FM
Oncotarget; 2013 Mar; 4(3):446-62. PubMed ID: 23530113
[TBL] [Abstract][Full Text] [Related]
19. TAZ Controls
Tiffon C; Giraud J; Molina-Castro SE; Peru S; Seeneevassen L; Sifré E; Staedel C; Bessède E; Dubus P; Mégraud F; Lehours P; Martin OCB; Varon C
Cells; 2020 Jun; 9(6):. PubMed ID: 32545795
[No Abstract] [Full Text] [Related]
20. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma.
Tsai SC; Lin CC; Shih TC; Tseng RJ; Yu MC; Lin YJ; Hsieh SY
Mol Carcinog; 2017 Sep; 56(9):2035-2047. PubMed ID: 28383782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
